Novaliq is a pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics. All first- and best-in-class ocular therapeutics are based on the patented EyeSol® technology. EyeSol® is the first and only water-free technology that overcomes the limitations of water-free eyedrops, improving the topical bioavailability, stability, and safety of traditionally unstable pharmaceutical ingredients. Semifluorinated alkanes (SFAs) form the basis for EyeSol® - scientific know-how made in Germany.
Care competences
Worldwide first water-free drug delivery technology (EyeSol®) overcoming limitations of water-based eyedrops
High product-development competence and integrated processes along the entire value-chain (from the development of the fomulation, the preclinical and clinical stages, all the way to the market)
Industry-leading product pipeline for Dry Eye Disease based on several new mechanisms of action (MoAs)
Significant platform value captured in extensive early stage pipeline in glaucoma and retinal diseases
Intensive and integrative, academic cooperation in the therapeutic area
